Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

S. M. Huijts, W. G. Boersma, D. E. Grobbee, W. C. Gruber, K. U

Cause‐specific long‐term mortality rates in patients recovered from community‐acquired pneumonia as compared with the general Dutch population A.H.W.

An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia A.R. Akram, J.D. Chalmers, J.K. Taylor, J. Rutherford,

Migrant health—a cause for concern?

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis G. Choudhury,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone.

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Non-antibiotic strategies for sepsis

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Targeted antibiotic management of ventilator-associated pneumonia

Impact of antibiotic restrictions: the pharmaceutical perspective

Vector control: a cornerstone in the malaria elimination campaign

Pharmacodynamics of doxycycline

Predictors for individual patient antibiotic treatment effect in hospitalized community- acquired pneumonia patients A.F. Simonetti, C.H. van Werkhoven,

Training for the infectious diseases speciality in Norway

Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients.

G. Höffken Clinical Microbiology and Infection

Community-acquired pneumonia: the evolving challenge

Does it make sense to detect Streptococcus pyogenes during tonsillitis in Europe to prevent acute rheumatic fever? S. Edouard, A. Michel-Lepage, D. Raoult

B. Gordts Clinical Microbiology and Infection

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

A. Potron, J. Kalpoe, L. Poirel, P. Nordmann

Metagenomics and probiotics

M. Aires-de-Sousa Clinical Microbiology and Infection

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

Systematic review of antibiotic consumption in acute care hospitals

Community-acquired pneumonia: epidemiologic and clinical consideration

The role of antimalarial treatment in the elimination of malaria

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Benchmarking inappropriate empirical antibiotic treatment

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Clinical infection services—the Leiden experience

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Community-acquired acute bacterial meningitis in the elderly in Turkey

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Presentation transcript:

Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands J.J. Oosterheert, M.J.M. Bonten, M.M.E. Schneider, I.M. Hoepelman Clinical Microbiology and Infection Volume 11, Issue 12, Pages 992-998 (December 2005) DOI: 10.1111/j.1469-0691.2005.01286.x Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Estimated antibiotic use (DDDs) for the treatment of community-acquired pneumonia in The Netherlands based on current practice and guidelines of the British Thoracic Society (BTS), the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS). Clinical Microbiology and Infection 2005 11, 992-998DOI: (10.1111/j.1469-0691.2005.01286.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions